MarketPeel
Insider Trading Intelligence
Pricing
…
JS

John P. Schmid

TRAX
DIRECTOR · FIRST TRACKS BIOTHERAPEUTICS, INC. · CIK 0001478916
FILING MIX · LIFETIME74%/26%
BUYS
62
SELLS
22
TOTAL VALUE
$2.35M
COMPANIES
5
ACTIVE SINCE
Feb 2020
HOLDINGS NOW
122,852
AVG SELL PX
$54.33
TRADE KIND
SHOWING 84 / 84
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
10 backtested trades · 8 horizons · 11 pending
Forward-return performance of every backtestable P/S trade by John P. Schmid, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d10+60.00%+11.18%+2.70%+8.48%+8.44%—
14d10+60.00%+15.66%+4.05%+11.61%+15.52%—
30d10+50.00%+29.88%+4.44%+25.44%+23.57%—
60d10+60.00%+32.48%+5.02%+18.10%+15.67%—
90d10+50.00%+38.87%+9.93%+28.94%+32.94%—
180d10(3 pending)+100.00%+51.38%+12.01%+39.37%+44.09%—
1y10(3 pending)+100.00%+123.04%+16.62%+106.42%+115.59%—
2y10(5 pending)+100.00%+223.41%+36.39%+187.02%+158.92%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
TRAX · 37,652 shares · as of Jun 15, 2026
010,50021,00031,50042,000SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 62 buys / 22 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ANAB
ANAPTYSBIO, INC
SALE
6,030——0Jun 15, 2026Jun 17, 2026 ↗View →
ANAB
ANAPTYSBIO, INC
PURCHASE
6,030——37,652Jun 15, 2026Jun 17, 2026 ↗View →
TRAX
FIRST TRACKS BIOTHERAPEUTICS, INC.
PURCHASE
6,030——37,652Jun 15, 2026Jun 17, 2026 ↗View →
TRAX
FIRST TRACKS BIOTHERAPEUTICS, INC.
SALE
6,030——0Jun 15, 2026Jun 17, 2026 ↗View →
DSGN
DESIGN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
30,000——30,000Jun 9, 2026Jun 11, 2026 ↗View →
TRAX
FIRST TRACKS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
42,000——42,000May 12, 2026May 14, 2026 ↗View →
TRAX
FIRST TRACKS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
15,000——15,000May 12, 2026May 14, 2026 ↗View →
TRAX
FIRST TRACKS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
7,000——7,000May 12, 2026Jun 12, 2026 ↗View →
TRAX
FIRST TRACKS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
2,500——2,500May 12, 2026Jun 12, 2026 ↗View →
TRAX
FIRST TRACKS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
4,000——4,000Apr 20, 2026Apr 22, 2026 ↗View →
ANAB
ANAPTYSBIO, INC
SALE
5,500——5,500Apr 20, 2026Apr 22, 2026 ↗View →
ANAB
ANAPTYSBIO, INC
PURCHASEGRANT
Stock grant
10,600——10,600Apr 20, 2026Apr 22, 2026 ↗View →
TRAX
FIRST TRACKS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
16,510——16,510Apr 20, 2026Apr 22, 2026 ↗View →
ANAB
ANAPTYSBIO, INC
PURCHASEGRANT
Stock grant
15,000——15,000Apr 20, 2026Apr 22, 2026 ↗View →
ANAB
ANAPTYSBIO, INC
SALE
10,600——10,600Apr 20, 2026Apr 22, 2026 ↗View →
TRAX
FIRST TRACKS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
9,200——9,200Apr 20, 2026Apr 22, 2026 ↗View →
ANAB
ANAPTYSBIO, INC
PURCHASEGRANT
Stock grant
11,000——11,000Apr 20, 2026Apr 22, 2026 ↗View →
TRAX
FIRST TRACKS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
11,000——11,000Apr 20, 2026Apr 22, 2026 ↗View →
ANAB
ANAPTYSBIO, INC
PURCHASEGRANT
Stock grant
6,000——6,000Apr 20, 2026Apr 22, 2026 ↗View →
TRAX
FIRST TRACKS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
10,600——10,600Apr 20, 2026Apr 22, 2026 ↗View →
ANAB
ANAPTYSBIO, INC
SALE
16,510——16,510Apr 20, 2026Apr 22, 2026 ↗View →
ANAB
ANAPTYSBIO, INC
SALE
9,200——9,200Apr 20, 2026Apr 22, 2026 ↗View →
ANAB
ANAPTYSBIO, INC
SALE
11,000——11,000Apr 20, 2026Apr 22, 2026 ↗View →
TRAX
FIRST TRACKS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
5,500——5,500Apr 20, 2026Apr 22, 2026 ↗View →
ANAB
ANAPTYSBIO, INC
PURCHASEGRANT
Stock grant
5,500——5,500Apr 20, 2026Apr 22, 2026 ↗View →
TRAX
FIRST TRACKS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
6,000——6,000Apr 20, 2026Apr 22, 2026 ↗View →
ANAB
ANAPTYSBIO, INC
PURCHASEGRANT
Stock grant
16,510——16,510Apr 20, 2026Apr 22, 2026 ↗View →
TRAX
FIRST TRACKS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
6,030——6,030Apr 20, 2026Apr 22, 2026 ↗View →
ANAB
ANAPTYSBIO, INC
PURCHASEGRANT
Stock grant
9,200——9,200Apr 20, 2026Apr 22, 2026 ↗View →
ANAB
ANAPTYSBIO, INC
SALE
15,000——15,000Apr 20, 2026Apr 22, 2026 ↗View →
ANAB
ANAPTYSBIO, INC
SALE
6,000——6,000Apr 20, 2026Apr 22, 2026 ↗View →
TRAX
FIRST TRACKS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
15,000——15,000Apr 20, 2026Apr 22, 2026 ↗View →
ANAB
ANAPTYSBIO, INC
SALE
12,596$55.71$701.7K39,671Mar 30, 2026Apr 1, 2026 ↗View →
ANAB
ANAPTYSBIO, INC
SALE
522$57.40$30.0K31,622Mar 30, 2026Apr 1, 2026 ↗View →
ANAB
ANAPTYSBIO, INC
SALE
7,527$56.70$426.8K32,144Mar 30, 2026Apr 1, 2026 ↗View →
ANAB
ANAPTYSBIO, INC
PURCHASEGRANT
Stock grant
4,000——4,000Jan 6, 2026Jan 8, 2026 ↗View →
ANAB
ANAPTYSBIO, INC
PURCHASEGRANT
Stock grant
5,500——5,500Jan 6, 2026Jan 8, 2026 ↗View →
ANAB
ANAPTYSBIO, INC
SALE
11,068$51.00$564.5K0Dec 23, 2025Dec 23, 2025 ↗View →
BBOT
BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.
SALE
30,000——0Aug 11, 2025Aug 11, 2025 ↗View →
BBOT
BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.
PURCHASE
30,000——30,000Aug 11, 2025Aug 11, 2025 ↗View →
ANAB
ANAPTYSBIO, INC
PURCHASE
6,030——52,267Jun 15, 2025Jun 17, 2025 ↗View →
ANAB
ANAPTYSBIO, INC
SALE
6,030——0Jun 15, 2025Jun 17, 2025 ↗View →
DSGN
DESIGN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
19,000——19,000Jun 10, 2025Jun 12, 2025 ↗View →
ANAB
ANAPTYSBIO, INC
PURCHASE
11,068$18.18$201.2K11,068Mar 25, 2025Mar 27, 2025 ↗View →
ANAB
ANAPTYSBIO, INC
SALE
20,645——0Jan 13, 2025Jan 15, 2025 ↗View →
ANAB
ANAPTYSBIO, INC
SALE
21,692——0Jan 13, 2025Jan 15, 2025 ↗View →
ANAB
ANAPTYSBIO, INC
PURCHASE
21,692$4.55$98.7K25,592Jan 13, 2025Jan 15, 2025 ↗View →
ANAB
ANAPTYSBIO, INC
PURCHASE
20,645$8.54$176.3K46,237Jan 13, 2025Jan 15, 2025 ↗View →
ANAB
ANAPTYSBIO, INC
PURCHASEGRANT
Stock grant
16,510——16,510Jan 7, 2025Jan 7, 2025 ↗View →
ANAB
ANAPTYSBIO, INC
PURCHASEGRANT
Stock grant
6,030——6,030Jan 7, 2025Jan 7, 2025 ↗View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASE
4,515$2.25$10.1K25,200Aug 12, 2024Aug 13, 2024 ↗View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASE
4,285$2.37$10.1K20,685Aug 9, 2024Aug 9, 2024 ↗View →
ANAB
ANAPTYSBIO, INC
PURCHASE
3,900——3,900Jun 15, 2024Jun 18, 2024 ↗View →
ANAB
ANAPTYSBIO, INC
SALE
3,900——0Jun 15, 2024Jun 18, 2024 ↗View →
DSGN
DESIGN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
19,000——19,000Jun 13, 2024Jun 17, 2024 ↗View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASEGRANT
Stock grant
50,000——113,159Jun 5, 2024Jun 5, 2024 ↗View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASE
5,400$1.91$10.3K16,400May 10, 2024May 10, 2024 ↗View →
DSGN
DESIGN THERAPEUTICS, INC.
PURCHASE
17,809$3.74$66.6K26,965Mar 25, 2024Mar 25, 2024 ↗View →
DSGN
DESIGN THERAPEUTICS, INC.
PURCHASE
9,156$3.62$33.1K9,156Mar 22, 2024Mar 25, 2024 ↗View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASE
4,500$2.16$9.7K11,000Mar 14, 2024Mar 14, 2024 ↗View →
ANAB
ANAPTYSBIO, INC
PURCHASEGRANT
Stock grant
6,030——6,030Jan 3, 2024Jan 5, 2024 ↗View →
ANAB
ANAPTYSBIO, INC
PURCHASEGRANT
Stock grant
16,510——16,510Jan 3, 2024Jan 5, 2024 ↗View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASE
6,500$1.51$9.8K6,500Nov 16, 2023Nov 17, 2023 ↗View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASEGRANT
Stock grant
42,500——63,159Jun 7, 2023Jun 7, 2023 ↗View →
DSGN
DESIGN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
15,000——15,000May 31, 2023Jun 2, 2023 ↗View →
ANAB
ANAPTYSBIO, INC
PURCHASEGRANT
Stock grant
3,900——3,900Jan 6, 2023Jan 10, 2023 ↗View →
ANAB
ANAPTYSBIO, INC
PURCHASEGRANT
Stock grant
10,600——10,600Jan 6, 2023Jan 10, 2023 ↗View →
DSGN
DESIGN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
15,000——15,000Jun 15, 2022Jun 16, 2022 ↗View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASEGRANT
Stock grant
25,000——25,000Jun 8, 2022Jun 9, 2022 ↗View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASEGRANT
Stock grant
15,000——20,659Jun 8, 2022Jun 9, 2022 ↗View →
ANAB
ANAPTYSBIO, INC
PURCHASEGRANT
Stock grant
9,200——9,200Feb 10, 2022Feb 14, 2022 ↗View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
SALE
20,000——0Oct 5, 2021Oct 5, 2021 ↗View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
SALE
11,228——0Oct 5, 2021Oct 5, 2021 ↗View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASEGRANT
Stock grant
11,228——11,228Oct 5, 2021Oct 5, 2021 ↗View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASEGRANT
Stock grant
20,000——20,000Oct 5, 2021Oct 5, 2021 ↗View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
SALE
25,220——0Oct 5, 2021Oct 5, 2021 ↗View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
SALE
5,659——0Oct 5, 2021Oct 5, 2021 ↗View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASEGRANT
Stock grant
25,220——25,220Oct 5, 2021Oct 5, 2021 ↗View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASEGRANT
Stock grant
5,659——5,659Oct 5, 2021Oct 5, 2021 ↗View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASEGRANT
Stock grant
11,228——11,228Jun 8, 2021Jun 8, 2021 ↗View →
DSGN
DESIGN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
15,000——15,000Mar 25, 2021Mar 26, 2021 ↗View →
ANAB
ANAPTYSBIO, INC
PURCHASEGRANT
Stock grant
11,000——11,000Feb 10, 2021Feb 12, 2021 ↗View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASEGRANT
Stock grant
11,228——11,228Jun 4, 2020Jun 4, 2020 ↗View →
ANAB
ANAPTYSBIO, INC
PURCHASEGRANT
Stock grant
11,000——11,000Feb 12, 2020Feb 13, 2020 ↗View →
Other insiders · TRAX
Loading peer insiders…
About this filer
CIK 0001478916
ROLE
Director
PRIMARY
TRAX
COMPANIES
5
ACTIVE SINCE
Feb 2020
MARKETPEEL · /INSIDER/0001478916DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback